Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147068 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
A Phase 1 study, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 392
- Enrollment target
NCT01147068 is a Phase 1 study that has completed, run by Protein Sciences Corporation. The registered enrollment target is 392 participants.
The verdict
NCT01147068, a Phase 1 study, has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 392 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at 4 dose levels in adjuvanted (GLA-SE) rHA formulations and 2 dose levels in unadjuvanted rHA formulations.
Interventions
- BIOLOGICAL 0.5mL Intramuscular Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147068
The ClinicalTrials.gov registry entry for NCT01147068 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 392 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protein Sciences Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 0.5mL Intramuscular Injection is the first listed.
NCT01147068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01147068 about?
NCT01147068 is a clinical study titled "Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults". The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at 4 dose levels in adjuvanted (GLA-SE) rHA formulations and 2 dose levels in unadjuvanted rHA formulations.
What is the current status of trial NCT01147068?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 392 participants. The study started on 2010-06. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01147068?
The interventions under investigation include: 0.5mL Intramuscular Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT01147068?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.